Sign up USA
Proactive Investors - Run By Investors For Investors

Pfizer tops Q4 hopes but lowers guidance for 2016

Revenue rose to US$14.05bn from US$13.1bn, also ahead of expectations of around US$13.6bn.
Pfizer tops Q4 hopes but lowers guidance for 2016
Pfizer is merging with Allergan

--- adds share price---

Pharma giant Pfizer (NYSE:PFE) beat expectations in its fourth quarter but tempered forecasts for the coming year.

The firm reported on Tuesday that fourth-quarter earnings halved compared to the previous year to US$61mln, or 10 cents per share (EPS), from US$1.22bn, or 19 cents per share.

However, the results include three months of legacy Hospira global operations, Pfizer said, and adjusted EPS was 53 cents per share, slightly ahead of hopes.

Revenue rose to US$14.05bn from US$13.1bn, also ahead of expectations of around US$13.6bn.

But for, 2016, the company said it expects "significant negative currency impact related to Venezuela."

Excluding the effects of its merger with Allergan, Pfizer said it expects adjusted EPS of US$2.20 to US$2.30, including the impact of currency headwinds, below estimates of US$2.38 per share.

Before the resumption of trading on Wall Street, shares were trading 1.7% lower in the pre-market trading, before nudging 0.77% higher in the regular session at US$30.21.

Jonny.jpg


Register here to be notified of future PFE Company articles
View full PFE profile

Pfizer Timeline

Article
November 23 2015

Related Articles

Diagnostic test
June 23 2016
The timetable for the HCV test trials is relatively short
World map made out of drugs
April 12 2016
The pharma services and drug development group has hit key milestones in the last year.
biotech_564b2dac17b4d.jpg
November 17 2015
Biotech Summit Therapeutics (LON:SUMM is edging closer to a huge 'inflection point', which could potentially transform its fortunes.
Copyright © Proactiveinvestors.com, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC